Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7524943 | 0.92 | ACHE (0.41) | ACHEPOLBALDH1A1L3MBTL1HTT | |
| SCHEMBL7531732 | 0.89 | ACHE (0.39) | ACHEPOLBALDH1A1L3MBTL1HTT | |
| SCHEMBL7531066 | 0.87 | ACHE (0.38) | ACHEPOLBALDH1A1SMN1; SMN2GAA | |
| SCHEMBL7664228 | 0.86 | ACHE (0.38) | ACHEPOLBNPC1MAPTRAB9A | |
| SCHEMBL7532824 | 0.86 | ACHE (0.37) | ACHEPOLBALDH1A1SMN1; SMN2GAA | |
| SCHEMBL7523234 | 0.82 | ALDH1A1 (0.36) | ACHEPOLBALDH1A1L3MBTL1HTR4 | |
| SCHEMBL7527004 | 0.82 | POLB (0.34) | ACHEPOLBALDH1A1L3MBTL1HTT | |
| SCHEMBL7509627 | 0.81 | SMN1; SMN2 (0.37) | ACHEPOLBALDH1A1L3MBTL1HTR4 | |
| SCHEMBL7529247 | 0.81 | THRB (0.37) | ACHEPOLBALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7666063 | 0.81 | ACHE (0.35) | ACHEPOLBALDH1A1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476226-B2 | PLATELET GLYCOPROTEIN IIB/IIIA FIBRINOGEN; ANTICOAGULANTS; THROMBOLYTIC AGENTS; THROMBOEMBOLIC DISORDERS; ANTIINFLAMMATORY AGENTS; BONE DISORDERS; ANTITUMOR, -METASTASIS, -ARTHRITIC AGENTS; ASTHMA; PSORIASIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-05 | — | — | US | claimed |
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-18 | — | — | US | claimed |
| US-6476226-B2 | PLATELET GLYCOPROTEIN IIB/IIIA FIBRINOGEN; ANTICOAGULANTS; THROMBOLYTIC AGENTS; THROMBOEMBOLIC DISORDERS; ANTIINFLAMMATORY AGENTS; BONE DISORDERS; ANTITUMOR, -METASTASIS, -ARTHRITIC AGENTS; ASTHMA; PSORIASIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-18 | — | — | US | disclosed |
| US-6303609-B1 | USED FOR THE INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | F13B, F11, FGB | ACHE 3785/4885POLB 3542/4885ALDH1A1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.